Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Deferred Revenue: 2018-2024

Historic Current Deferred Revenue for RedHill Biopharma (RDHL) over the last 7 years, with Dec 2024 value amounting to $9.3 million.

  • RedHill Biopharma's Current Deferred Revenue rose 486.59% to $10.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.5 million, marking a year-over-year increase of 486.59%. This contributed to the annual value of $9.3 million for FY2024, which is 12.82% down from last year.
  • Per RedHill Biopharma's latest filing, its Current Deferred Revenue stood at $9.3 million for FY2024, which was down 12.82% from $10.7 million recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's Current Deferred Revenue ranged from a high of $47.9 million in FY2022 and a low of $9.3 million during FY2024.
  • Its 3-year average for Current Deferred Revenue is $22.6 million, with a median of $10.7 million in 2023.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 1,347.75% in 2020, then tumbled by 77.74% in 2023.
  • RedHill Biopharma's Current Deferred Revenue (Yearly) stood at $18.3 million in 2020, then surged by 67.43% to $30.7 million in 2021, then soared by 55.87% to $47.9 million in 2022, then slumped by 77.74% to $10.7 million in 2023, then dropped by 12.82% to $9.3 million in 2024.